Christopher McGuigan

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 157 citations · Full text

Disease Progression, Medicine, Systemic Treatment +9

The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.

Christopher McGuigan, Michael Hutchinson · PubMed · 2004 · 141 citations · Full text

Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity

Christopher McGuigan · Journal of Neurology Neurosurgery & Psychiatry · 2004 · 80 citations · Full text

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

Maciej Juryńczyk, Brian G. Weinshenker, Gülşen Akman‐Demir et al. · Journal of Neurology · 2015 · 62 citations

Autoimmune Disease, Neurological Disorder, Diagnostic Approaches +12